The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

A decision is expected in the fourth quarter of 2025.

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

A batch of the drug is under a limited voluntary recall after a shipping error exposed certain doses to improper temperatures.